Better Evidence for Selecting Transplant Fluids
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 808 participants.
Also called NCT03829488
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 808 participants
- Registry
-
NCT03829488 -
ACTRN12617000358347
-
- Other papers using this trial's data
- Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT03829488. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-26 (actual); primary completion 2021-07-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Better Evidence for Selecting Transplant Fluids
- Acronym
- BEST-Fluids
- Condition
- End Stage Kidney Disease
- Condition
- Delayed Graft Function
- Condition
- Kidney Transplant; Complications
- Intervention (Drug)
- Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
- Intervention (Drug)
- 0.9% SODIUM CHLORIDE 9g/L injection BP
- Lead sponsor
- The University of Queensland
- Collaborator
- Australian Government Department of Health and Ageing
- Collaborator
- Health Research Council, New Zealand
- Collaborator
- Baxter Healthcare Corporation
Record details
- Record id
cardio:ct-nct03829488- Content hash
d515c1cdbbaae532a207726a08642420393422bc1b902d435db68fcde2af5c55